Evidence map›Paper›PMID 41074590›Full record

ArticleActa biochimica et biophysica Sinica2025

EOAI3402143 inhibits lung adenocarcinoma progression through the NF-κB/NR4A1 pathway.

Jia Xu, Wenjun Liu, Li Chen, Juan Zhang, Dongze Zhang, Haitao Huang, Xiaoming Zhang, Xue Huang, Guangbo Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jia XuJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Wenjun LiuJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Li ChenJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Juan ZhangJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Dongze ZhangJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Haitao HuangDepartment of Thoracic Surgery, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.
Xiaoming ZhangShanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai 200031, China.
Xue HuangJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Guangbo ZhangJiangsu Institute of Clinical Immunology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is currently the cancer with the highest morbidity and mortality rates in the world, and its targeted therapy, although effective, is limited in the types of targeted drugs and prone to drug resistance in treated patients. Therefore, the continuous discovery of new targeted therapeutic agents is particularly crucial for the treatment of LUAD. Here, we aim to investigate the antitumor effect of EOAI3402143 on LUAD and the potential mechanism of its action. We use flow cytometry to analyze apoptosis, transwell and colony formation assays to detect cell migration, invasion and proliferation ability; western blot, RT-qPCR and RNA-seq to analyze the signaling pathways involved in EOAI3402143; and

Indexed as

EOAI3402143lung adenocarcinomaNF-κBNR4A1

Identifiers

PMID41074590
PMCPMC13107016

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.